ESOC 2022

Lys Therapeutics announces to attend the 8th European Stroke Organisation Conference (ESOC 2022, 4-6 May 2021, LYON France).

Dr. Manuel BLANC, Pr. Denis VIVIEN, Dr. Flavie Lesept and Dr. Fanny Potzeha are happy to meet you there.

💪 All together against Stroke and its dramatic consequences.

https://2022.eso-conference.org/ —

Oral presentation – ESOC 2022

🔬🧠 “Does reversing vascular dysfunction help prevent neurodegeneration? Insights from preclinical models”

🎤 *Pr. Denis VIVIEN*, head of the bb@c, Blood and Brain Caen normandie Institute and Head of Science of Lys Therapeutics is presenting today new promising preclinical data during the 8th European Stroke Organisation Conference (#ESOC2022) with our lead candidate Glunomab in ischemic stroke including with diabetes, an important comorbidity among stroke patients :

To be followed today at 5pm, physically and in digital during #ESOC2022 conference in the #EAN#ESO Joint Symposium: “The vascular side of neurodegeneration: a preclinical and clinical perspective”

Scientific poster – ESOC 2022

Lys Therapeutics is reinforcing its neurovascular business unit with new promising preclinical data presented during the 8th European Stroke Organisation Conference (#ESOC2022) for its lead candidate Glunomab in ischemic stroke including with diabetes, an important comorbidity among stroke patients.

Dr. Manuel BLANC, Pr. Denis VIVIEN, Dr. Flavie Lesept, Dr. Fanny Potzeha and Florent Lebrun are happy to meet you there.